++
For further information, see CMDT Part 39-09: Esophageal Cancer
+++
Essentials of Diagnosis
++
+++
General Considerations
++
++
Occurs usually in persons between 50 and 70 years of age
Ratio of men to women is 3:1
About 18,440 new cases of esophageal cancer were diagnosed in 2020
Adenocarcinoma is more common in North America as well as Northern and Western European countries
++
Solid food dysphagia (> 90%)
Odynophagia
Significant weight loss
Coughing on swallowing or recurrent pneumonia suggests tracheoesophageal fistula from local tumor extension
Chest or back pain suggest mediastinal extension
Hoarseness suggests recurrent laryngeal nerve involvement
Physical examination often unrevealing
Supraclavicular or cervical lymphadenopathy or hepatomegaly suggests metastatic disease
+++
Differential Diagnosis
++
Peptic stricture
Achalasia
Adenocarcinoma of gastric cardia with esophageal involvement
Esophageal web, ring (eg, Schatzki), or diverticulum
++
++
Chest radiographs may show adenopathy
Barium esophagogram
Contrast CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension
Positron emission tomography with fluorodeoxyglucose (FDG-PET) or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized disease after other diagnostic studies
+++
Diagnostic Procedures
++
Upper endoscopy with biopsy
Endoscopic ultrasonography with guided fine-needle aspiration (FNA) of lymph nodes is superior to CT for evaluating local extension and lymph node involvement
Bronchoscopy may be required to exclude tracheobronchial extension
Laparoscopy to exclude occult peritoneal carcinomatosis should be considered in tumors at gastroesophageal junction
++
Chemotherapy (cisplatin and fluorouracil) plus radiation therapy for patients with "curable" disease who are poor surgical candidates
Combination chemotherapy may be considered in those patients with metastatic disease who still have good functional status and expected survival of at least several months
For patients with poor functional status, single-agent therapy with a fluoropyrimidine, a taxane, or irinotecan may be used
Trastuzumab may be added to standard regimens when patients have metastatic distal esophageal and ...